Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 976 to 990 of 2186 results for guidelines

  1. Non-Hodgkin's lymphoma: rituximab subcutaneous injection (ESNM46)

    Summary of the evidence on rituximab subcutaneous injection for non-Hodgkin's lymphoma in adults to inform local NHS planning and decision-making

  2. Atrial fibrillation and heart valve disease: self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system) (HTG353)

    Evidence-based recommendations on the CoaguChek XS system for self-monitoring coagulation status in adults and children. The recommendations originally included the InRatio2 PT/INR, but this was withdrawn from the market in October 2016 and is not currently available.

  3. Apremilast for treating moderate to severe plaque psoriasis (TA419)

    Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults.

  4. Cardiovascular disease prevention: risk assessment (modifiable risk factors) (IND270)

    This indicator covers the percentage of people aged 43 to 84 years with a modifiable risk factor who have a recorded cardiovascular disease (CVD) risk assessment score in the preceding 3 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  5. NICE guidance implementation toolkits

    up to 5 years This toolkit helps healthcare providers implement NICE guideline NG247: improving antenatal care, reducing inequalities,...

  6. Rapid tests for group A streptococcal infections in people with a sore throat (HTG531)

    Evidence-based recommendations on rapid tests for group A streptococcal infections in people aged 5 and over with a sore throat.

  7. Should women having a surgical abortion up to and including 10 +0  weeks' gestation have anti-D prophylaxis if they are RhD (or D) negative?

    with significant variation between different international and national guidelines. Current practice in the NHS is to give anti-D to all...

  8. AMBLor for identifying low-risk non-ulcerated early-stage cutaneous melanomas (MIB294)

    NICE has developed a medtech innovation briefing (MIB) on AMBLor for identifying low-risk non-ulcerated early-stage cutaneous melanomas .

  9. FreeStyle Libre for glucose monitoring (MIB110)

    NICE has developed a medtech innovation briefing (MIB) on FreeStyle Libre for glucose monitoring .

  10. ImmunoCAP ISAC 112 for multiplex allergen testing (HTG413)

    Evidence-based recommendations on multiplex allergen testing, using ImmunoCAP ISAC 112 in people with allergy that is difficult to diagnose.

  11. Tenofovir disoproxil for the treatment of chronic hepatitis B (TA173)

    Evidence-based recommendations on tenofovir disoproxil for treating chronic hepatitis B.

  12. Frequency of application of topical corticosteroids for atopic eczema (TA81)

    Evidence-based recommendations on using topical corticosteroids for people with atopic eczema.

  13. Technology appraisal data: cancer appraisal recommendations

    Data on the cancer recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.

  14. Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion (TA283)

    Evidence-based recommendations on ranibizumab (Lucentis) for treating visual impairment caused by macular oedema secondary to retinal vein occlusion in adults.

  15. Resource planner

    Our resource planner tool to help you plan for and implement NICE guidance.